Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Celldex Therapeutics Inc (NASDAQ:CLDX)

3.33
Delayed Data
As of Mar 24
 +0.06 / +1.83%
Today’s Change
2.85
Today|||52-Week Range
5.13
-5.93%
Year-to-Date
Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat
Mar 15 / Zacks.com - Paid Partner Content
3 Horrible Stocks for Retirees
Mar 12 / MotleyFool.com - Paid Partner Content
Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies Progre...
Mar 14 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close3.27
Today’s open3.29
Day’s range3.22 - 3.33
Volume1,281,042
Average volume (3 months)2,022,278
Market cap$410.3M
Dividend yield--
Data as of 4:14pm ET, 03/24/2017

Growth & Valuation

Earnings growth (last year)+3.05%
Earnings growth (this year)+5.29%
Earnings growth (next 5 years)--
Revenue growth (last year)+23.83%
P/E ratioNM
Price/Sales52.96
Price/Book1.51

Competitors

 Today’s
change
Today’s
% change
LNTHLantheus Holdings In...0.000.00%
OXFDOxford Immunotec Glo...-0.09-0.58%
VCYTVeracyte Inc+0.06+0.66%
CALACalithera Bioscience...+0.15+1.46%
Data as of 3:59pm ET, 03/24/2017

Financials

Next reporting dateMay 4, 2017
EPS forecast (this quarter)-$0.28
Annual revenue (last year)$6.8M
Annual profit (last year)-$128.5M
Net profit margin-1,894.05%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Anthony S. Marucci
CFO, Secretary, Treasurer &
Senior Vice President
Avery W. Catlin
Corporate headquarters
Hampton, New Jersey

Forecasts


Search for Jobs